GLP-1 in the Hypothalamic Paraventricular Nucleus Promotes Sympathetic Activation and Hypertension

• Published in: The Journal of neuroscience Vol. 44; no. 21; p. e2032232024
• Main Authors: Xu, Xiao-Yu, Wang, Jing-Xiao, Chen, Jun-Liu, Dai, Min, Wang, Yi-Ming, Chen, Qi, Li, Yue-Hua, Zhu, Guo-Qing, Chen, Ai-Dong
• Format: Journal Article
• Language: English
• Published: United States Society for Neuroscience 22.05.2024
• Subjects: Acetylcysteine; Adenylate cyclase; Agonists; Animals; Antagonists; Blood pressure; Blood Pressure - drug effects; Blood Pressure - physiology; Cyclic AMP; Diabetes mellitus; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide 1 - metabolism; Glucagon-Like Peptide-1 Receptor - antagonists & inhibitors; Glucagon-Like Peptide-1 Receptor - metabolism; Hypertension; Hypertension - metabolism; Hypertension - physiopathology; Hypothalamus; Kinases; Male; Microinjection; NAD(P)H oxidase; Outflow; Oxidase; Paraventricular Hypothalamic Nucleus - drug effects; Paraventricular Hypothalamic Nucleus - metabolism; Paraventricular nucleus; Protein kinase A; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Renal plexus; Superoxide; Sympathetic nerves; Sympathetic Nervous System - drug effects; Sympathetic Nervous System - physiology; Tempol; blood pressure; sympathetic activity; GLP-1; hypertension; reactive oxygen species; paraventricular nucleus
• ISSN: 0270-6474; 1529-2401
• DOI: 10.1523/JNEUROSCI.2032-23.2024

Glucagon-like peptide-1 (GLP-1) and its analogs are widely used for diabetes treatment. The paraventricular nucleus (PVN) is crucial for regulating cardiovascular activity. This study aims to determine the roles of GLP-1 and its receptors (GLP-1R) in the PVN in regulating sympathetic outflow and blood pressure. Experiments were carried out in male normotensive rats and spontaneously hypertensive rats (SHR). Renal sympathetic nerve activity (RSNA) and mean arterial pressure (MAP) were recorded. GLP-1 and GLP-1R expressions were present in the PVN. PVN microinjection of GLP-1R agonist recombinant human GLP-1 (rhGLP-1) or EX-4 increased RSNA and MAP, which were prevented by GLP-1R antagonist exendin 9-39 (EX9-39) or GLP-1R antagonist 1, superoxide scavenger tempol, antioxidant N-acetylcysteine, NADPH oxidase (NOX) inhibitor apocynin, adenylyl cyclase (AC) inhibitor SQ22536 or protein kinase A (PKA) inhibitor H89. PVN microinjection of rhGLP-1 increased superoxide production, NADPH oxidase activity, cAMP level, AC, and PKA activity, which were prevented by SQ22536 or H89. GLP-1 and GLP-1R were upregulated in the PVN of SHR. PVN microinjection of GLP-1 agonist increased RSNA and MAP in both WKY and SHR, but GLP-1 antagonists caused greater effects in reducing RSNA and MAP in SHR than in WKY. The increased superoxide production and NADPH oxidase activity in the PVN of SHR were augmented by GLP-1R agonists but attenuated by GLP-1R antagonists. These results indicate that activation of GLP-1R in the PVN increased sympathetic outflow and blood pressure via cAMP-PKA-mediated NADPH oxidase activation and subsequent superoxide production. GLP-1 and GLP-1R upregulation in the PVN partially contributes to sympathetic overactivity and hypertension.